A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R″—C(O)
A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R″—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R′ and R″ independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.
대표청구항▼
What is claimed is: 1. An indoline-sulfonamide compound of the following formula (I): wherein R1 is H, or halogen; R2 is H, Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), R″—C(O)—, and Ar is substituted or unsub
What is claimed is: 1. An indoline-sulfonamide compound of the following formula (I): wherein R1 is H, or halogen; R2 is H, Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), R″—C(O)—, and Ar is substituted or unsubstituted C5-C20 aryl, cyclyl, R′ and R″ independently, is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 are C5-C15 aryl or C1-C10 alkyl. 2. The compound as claimed in claim 1, wherein R1 is H or Br. 3. The compound as claimed in claim 1, wherein Ar is unsubstituted phenyl. 4. The compound as claimed in claim 1, wherein Ar is substituted or unsubstituted C5-C8 aryl. 5. The compound as claimed in claim 1, wherein Ar is aryl with a substituent, and the substituent is halogen, nitro, cyano, alkoxyl, acetoxyl (CH3CO2−), or oxyl. 6. The compound as claimed in claim 1, wherein the halogen is F, Cl, or Br. 7. The compound as claimed in claim 1, wherein R2 is benzoyl, fluorobenzoyl, nitrobenzoyl, cyanobenzoyl, methoxybenzoyl, or acetylbenzoyl. 8. The compound as claimed in claim 1, wherein R2 is isonicotinoyl, N-oxide-isonicotinoyl, furoyl, or thienoyl. 9. The compound as claimed in claim 1, wherein R2 is benzenesulfonyl, nitrobenzenesulfonyl, or fluorobenzenesulfonyl. 10. The compound as claimed in claim 1, wherein R2 is (CO)OC6H5, or (CO)N(CH3)C6H5. 11. The compound as claimed in claim 1, wherein R2 is benzyl, acetyl, or pivaloyl. 12. The compound as claimed in claim 1, wherein R3 is C1-C10 alkyl. 13. The compound as claimed in claim 12, wherein R3 is methyl. 14. The compound as claimed in claim 1, wherein the compound is 1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine. 15. The compound as claimed in claim 1, wherein the compound is 1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine, 4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzamide, N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-benzamide, 4-Cyano-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzamide, 4-Methoxy-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzamide, or N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-terephthalamic acid methyl ester. 16. The compound as claimed in claim 1, wherein the compound is N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide, Furan-2-carboxylic acid [1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amide, or Thiophene-2-carboxylic acid [1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amide. 17. The compound as claimed in claim 1, wherein the compound is N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzenesulfonamide, N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]4-nitro-benzenesulfon amide, or 4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzenesulfonamide. 18. The compound as claimed in claim 1, wherein the compound is [1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-carbamic acid phenyl ester, or 3-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-1-methyl-1-phenyl-urea. 19. The compound as claimed in claim 1, wherein the compound is Benzyl-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amine, N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-acetamide, or N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-2,2-dimethyl-propionamide. 20. The compound as claimed in claim 1, wherein the compound is N-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide, Furan-2-carboxylic acid [5-bromo-1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amide, or N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-N-oxide-isonicotinamide. 21. The compound as claimed in claim 1, wherein the compound is a cellular tubulin polymerization the term inhibitor. 22. The compound as claimed in claim 1, wherein the compound is a tubulin polymerization related cancer the term inhibitor. 23. The compound as claimed in claim 1, wherein the compound is combined with a pharmaceutically acceptable carrier to provide a pharmaceutical composition. 24. The compound as claimed in claim 1, wherein Ar is C5-C8 aryl, or C5-C8 cyclyl. 25. The compound of claim 1 wherein R1 is H, R2 is H and R3 is methyl.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허를 인용한 특허 (14)
Aicher, Thomas D.; VanHuis, Chad A.; MacLean, John; Andresen, Brian M.; Barr, Kenneth J.; Bienstock, Corey; Anthony, Neville J.; Daniels, Matthew; Liu, Yuan; White, Catherine; Lapointe, Blair T.; Sciammetta, Nunzio; Simov, Vladimir; Trotter, Wesley B.; Liu, Kun, 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease.
Aicher, Thomas D.; Skalitzky, Donald J.; Taylor, Clarke B.; Van Huis, Chad A., Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease.
Aicher, Thomas D.; VanHuis, Chad A.; MacLean, John; Andresen, Brian M.; Barr, Kenneth J.; Bienstock, Corey; Daniels, Matthew; Liu, Kun; Liu, Yuan; White, Catherine; Sciammetta, Nunzio; Simov, Vladimir, Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease.
Glick, Gary D.; Toogood, Peter L.; Romero, Arthur G.; Van Huis, Chad A.; Aicher, Thomas D.; Kaub, Carl; Mattson, Matthew N.; Thomas, William D.; Stein, Karin A.; Krogh-Jespersen, Erik; Wang, Zhan, N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease.
Aicher, Thomas D.; Toogood, Peter L.; Hu, Xiao, Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease.
Aicher, Thomas D.; Toogood, Peter L.; Hu, Xiao, Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease.
Aicher, Thomas D.; Toogood, Peter L.; Hu, Xiao, Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease.
Aicher, Thomas D.; Barr, Kenneth J.; Lapointe, Blair T.; Simov, Vladimir; Stein, Karin A.; Thomas, William D.; Toogood, Peter L.; Van Huis, Chad A.; White, Catherine M., Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease.
Aicher, Thomas D.; VanHuis, Chad A.; Thomas, William D.; MacLean, John K.; Andresen, Brian M.; Barr, Kenneth J.; Bienstock, Corey E.; Anthony, Neville J.; Daniels, Matthew; Liu, Kun; Liu, Yuan; White, Catherine M.; Lapointe, Blair T.; Sciammetta, Nunzio; Simov, Vladimir, Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease.
Aicher, Thomas D.; VanHuis, Chad A.; Thomas, William D.; MacLean, John K.; Andresen, Brian M.; Barr, Kenneth J.; Bienstock, Corey E.; Anthony, Neville J.; Daniels, Matthew; Liu, Kun; Liu, Yuan; White, Catherine M.; Lapointe, Blair T.; Sciammetta, Nunzio; Simov, Vladimir, Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease.
Aicher, Thomas D.; Taylor, Clarke B.; VanHuis, Chad A., Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.